Prevalence and predictors of lipid abnormalities in patients treated with statins in the UK general practice

Atherosclerosis

Volumn 202, Issue 1, 2009, Pages 225-233

  Phatak, H ^a   Wentworth, C ^b   Sazonov, V ^a   Burke, T ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Analytic Consulting Solutions   (United States)

Author keywords

HDL C; TG; UK general practice

Indexed keywords

HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

ADULT; AGED; ARTICLE; BODY MASS; CHOLESTEROL BLOOD LEVEL; COMORBIDITY; CONTROLLED STUDY; DEMOGRAPHY; DISEASE PREDISPOSITION; DISORDERS OF LIPID AND LIPOPROTEIN METABOLISM; FEMALE; HUMAN; HYPERTENSION; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; OBESITY; PREVALENCE; PRIORITY JOURNAL; RISK ASSESSMENT; SMOKING; TRIACYLGLYCEROL BLOOD LEVEL; UNITED KINGDOM;

AGED; COHORT STUDIES; CORONARY DISEASE; DYSLIPIDEMIAS; FAMILY PRACTICE; FEMALE; GREAT BRITAIN; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERTENSION; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; SMOKING; TREATMENT OUTCOME;

EID: 57749179983     PISSN: 00219150     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2008.03.016     Document Type: Article

References (30)

1. National Health Service U. Prodigy guidance: coronary heart disease - identification and management. Prodigy Guidance: National Health Service, Department of Health; 2003. Available at URL: http://www.prodigy.nhs.uk/guidance.asp?gt=Coronary%20heart%20disease%20r isk%20-%20identification%20and%20management#9420. Accessed December 5, 2005.
2. Deaths by cause, sex and age. United Kingdom. British Heart Foundation 2006; 2003. Available at URL: http://www.heartstats.org. Accessed January 1, 2006.
3. Primatesta P., and Poulter N. Lipid concentrations and the use of lipid lowering drugs: evidence from a national cross sectional survey. BMJ 321 (2000) 1322-1325
4. Wood D., Durrington P., McInnes G., et al. Joint British recommendations on prevention of coronary heart disease in clinical practice. Heart 80 Suppl. 2 (1998) S1-S29
5. Grundy S.M., Cleeman J.I., Bairey Merz M., et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. J Am Coll Cardiol 44 (2004) 720-732
6. Backer G.D., Ambrosioni E., Borch-Johnsen K., et al. European guidelines on cardiovascular disease prevention in clinical practice: Third Joint Task Force of European and other Societies on Cardiovascular Disease prevention in Clinical Practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil 10 Suppl. 1 (2003) S1-S78
7. Jick H., Jick S.S., and Derby L.E. Validation of information recorded on general practitioner based computerised data sources in the United Kingdom. BMJ 302 (1991) 766-768
8. Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 285 (2001) 2486-2497
9. British Cardiac Society, British Hypertension Society, Diabetes UK, HEART UK, Primary Care Cardiovascular Society, The Stroke Association. JBS 2: Joint British Societies' guidelines on prevention of cardiovascular disease in clinical practice. Heart Online 2005; 91:1-52.
10. De Backer G. Evidence-based goals versus achievement in clinical practice in secondary prevention of coronary heart disease: findings of EUROASPIRE II. Atheroscler Suppl 2 4 (2002) 13-17
11. Straka R.J., Taheri R., Cooper S.L., Tan A.W., and Smith A.C. Assessment of hypercholesterolemia control in a managed care organization. Pharmacotherapy 21 7 (2001) 818-827
12. Sueta C.A., Chowdhury M., Boccuzzi S.J., et al. Analysis of the degree of undertreatment of hyperlipidemia and congestive heart failure secondary to coronary artery disease. Am J Cardiol 83 9 (1999) 1303-1307
13. National Cholesterol Education Program (NCEP) Expert Panel on Detection Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). Third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report. Circulation 106 (2002) 3143-3221
14. Downs J.R., Clearfield M., Weis S., et al. Primary prevention of acute coronary events with Lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. JAMA 279 (1998) 1615-1622
15. Assmann G., Cullen P., and Schulte H. Simple scoring scheme for calculating the risk of acute coronary events based on the 10-year follow-up of the Prospective Cardiovascular Munster (PROCAM) study. Circulation 105 (2002) 310-315
16. D'Agostino R.B., Russell M.W., Huse D.M., et al. Primary and subsequent coronary risk appraisal: new results from the Framingham study. Am Heart J 139 (2000) 272-281
17. Anderson K.M., Odell P.M., Wilson P.W.F., and Kannel W.B. Cardiovascular disease risk profiles. Am Heart J 121 (1990) 293-298
18. Barter P., Gotto A.M., LaRosa J.C., et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 357 13 (2007) 1301-1310 [September 27]
19. Hokanson J.E., and Austin M.A. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 3 (1996) 213-219
20. Assmann G., Cullen P., and Schulte H. The Munster Heart Study (PROCAM) - results of follow-up at 8 years. Eur Heart J 19 (1998) A2-A11
21. Cullen P. Evidence that triglycerides are an independent coronary heart disease risk factor. Am J Cardiol 86 (2000) 943-949
22. Castelli W.P. The triglyceride issue: a view from Framingham. Am Heart J 112 (1986) 432-437
23. Yarnell J.W.G., Patterson C.C., Sweetnam P.M., et al. Do total and high density lipoprotein cholesterol and triglycerides act independently in the prediction of ischemic heart disease? Ten-year follow-up of Caerphilly and Speedwell cohorts. Arterioscler Thromb Vasc Biol 21 (2001) 1340-1345
24. Maki K.C., Galant R., and Davidson M.H. Non-high-density lipoprotein cholesterol: the forgotten therapeutic target. Am J Cardiol 96 Suppl. (2005) 59K-64K
25. Miller M, Cannon CP, Ray K, et al. Impact of Triglycerides in PROVE-IT TIMI-22: does TG <150 improve CHD risk beyond LDL <70? Circulation 114[18 Supplement II [AHA proceedings]], II-290; 2006 [Abstract].
26. Williams B., Poulter N.R., Brown M.J., et al. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004 BHS IV. J Hum Hypertens 18 (2004) 139-185
27. Fonseca F.A.H., Ruiz A., Cardona-Munoz E.G., et al. The DISCOVERY PENTA study: a Direct Statin COmparison of LDL-C Value - an Evaluation of Rosuvastatin therapY compared with atorvastatin. Curr Med Res Opin 21 8 (2005) 1307-1315
28. Shepherd J., Betteridge J., and Van Gaal L. Nicotinic acid in the management of dyslipidemia associated with diabetes and metabolic syndrome: a position paper developed by a European consensus panel. Curr Med Res Opin 21 5 (2005) 665-682
29. Brijmohun R.S., Hutten B.A., Kastelein J.J., and Stroes E.S. Efficacy and safety of high-density lipoprotein cholesterol-increasing compounds: a meta-analysis of randomized controlled trials. J Am Coll Cardiol 45 2 (2005) 185-197
30. Ridker P.M. Fasting versus nonfasting triglycerides and the prediction of cardiovascular risk: do we need to revisit the oral triglyceride tolerance test?. Clin Chem 54 1 (2008) 11-13